These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1581 related articles for article (PubMed ID: 32244180)

  • 21. The prevalence of metabolic disorders in various phenotypes of polycystic ovary syndrome: a community based study in Southwest of Iran.
    Tehrani FR; Rashidi H; Khomami MB; Tohidi M; Azizi F
    Reprod Biol Endocrinol; 2014 Sep; 12():89. PubMed ID: 25224635
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thiazolidinediones for the therapeutic management of polycystic ovary syndrome : impact on metabolic and reproductive abnormalities.
    Elkind-Hirsch KE
    Treat Endocrinol; 2006; 5(3):171-87. PubMed ID: 16677059
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Androgens in polycystic ovary syndrome: the role of exercise and diet.
    Giallauria F; Palomba S; Vigorito C; Tafuri MG; Colao A; Lombardi G; Orio F
    Semin Reprod Med; 2009 Jul; 27(4):306-15. PubMed ID: 19530064
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polycystic ovary syndrome: reviewing diagnosis and management of metabolic disturbances.
    Spritzer PM
    Arq Bras Endocrinol Metabol; 2014 Mar; 58(2):182-7. PubMed ID: 24830595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of hyperandrogenism in female obesity and cardiometabolic diseases associated with polycystic ovary syndrome.
    Barber TM; Vojtechova P; Franks S
    Horm Mol Biol Clin Investig; 2013 Sep; 15(3):91-103. PubMed ID: 25436736
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The polycystic ovary syndrome: a position statement from the European Society of Endocrinology.
    Conway G; Dewailly D; Diamanti-Kandarakis E; Escobar-Morreale HF; Franks S; Gambineri A; Kelestimur F; Macut D; Micic D; Pasquali R; Pfeifer M; Pignatelli D; Pugeat M; Yildiz BO;
    Eur J Endocrinol; 2014 Oct; 171(4):P1-29. PubMed ID: 24849517
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adrenal androgen excess and body mass index in polycystic ovary syndrome.
    Moran C; Arriaga M; Arechavaleta-Velasco F; Moran S
    J Clin Endocrinol Metab; 2015 Mar; 100(3):942-50. PubMed ID: 25514100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Best methods for identification and treatment of PCOS.
    Artini PG; Di Berardino OM; Simi G; Papini F; Ruggiero M; Monteleone P; Cela V
    Minerva Ginecol; 2010 Feb; 62(1):33-48. PubMed ID: 20186113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polycystic ovary syndrome and metabolic comorbidities: therapeutic options.
    De Leo V; Musacchio MC; Palermo V; Di Sabatino A; Morgante G; Petraglia F
    Drugs Today (Barc); 2009 Oct; 45(10):763-75. PubMed ID: 20069140
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Investigation of common risk factors between polycystic ovary syndrome and Alzheimer's disease: a narrative review.
    Sarahian N; Sarvazad H; Sajadi E; Rahnejat N; Eskandari Roozbahani N
    Reprod Health; 2021 Jul; 18(1):156. PubMed ID: 34311759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolic Syndrome in Polycystic Ovary Syndrome.
    Pasquali R
    Front Horm Res; 2018; 49():114-130. PubMed ID: 29894990
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polycystic Ovary Syndrome as a systemic disease with multiple molecular pathways: a narrative review.
    Carvalho LML; Dos Reis FM; Candido AL; Nunes FFC; Ferreira CN; Gomes KB
    Endocr Regul; 2018 Oct; 52(4):208-221. PubMed ID: 31517612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polycystic ovary syndrome: treatment strategies and management.
    Escobar-Morreale HF
    Expert Opin Pharmacother; 2008 Dec; 9(17):2995-3008. PubMed ID: 19013863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of reproductive, metabolic, and endocrine features of polycystic ovary syndrome in female hyperandrogenic mouse models.
    Caldwell AS; Middleton LJ; Jimenez M; Desai R; McMahon AC; Allan CM; Handelsman DJ; Walters KA
    Endocrinology; 2014 Aug; 155(8):3146-59. PubMed ID: 24877633
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The value of the free androgen index depends on the phenotype of polycystic ovary syndrome - a single-centre experience.
    Ożga K; Krzyczkowska-Sendrakowska M; Hubalewska-Dydejczyk A; Gilis-Januszewska A; Ratajczak M; Ratajczak M; Chaykivska Z; Jach R
    Endokrynol Pol; 2019; 70(4):330-335. PubMed ID: 30938834
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polycystic ovary syndrome, adipose tissue and metabolic syndrome.
    Delitala AP; Capobianco G; Delitala G; Cherchi PL; Dessole S
    Arch Gynecol Obstet; 2017 Sep; 296(3):405-419. PubMed ID: 28643028
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiometabolic Risks in Polycystic Ovary Syndrome: Non-Traditional Risk Factors and the Impact of Obesity.
    Chiu WL; Boyle J; Vincent A; Teede H; Moran LJ
    Neuroendocrinology; 2017; 104(4):412-424. PubMed ID: 28006770
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges.
    Jeanes YM; Reeves S
    Nutr Res Rev; 2017 Jun; 30(1):97-105. PubMed ID: 28222828
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ovarian and adipose tissue dysfunction in polycystic ovary syndrome: report of the 4th special scientific meeting of the Androgen Excess and PCOS Society.
    Yildiz BO; Azziz R;
    Fertil Steril; 2010 Jul; 94(2):690-3. PubMed ID: 19394000
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polycystic ovary syndrome.
    Azziz R; Carmina E; Chen Z; Dunaif A; Laven JS; Legro RS; Lizneva D; Natterson-Horowtiz B; Teede HJ; Yildiz BO
    Nat Rev Dis Primers; 2016 Aug; 2():16057. PubMed ID: 27510637
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 80.